Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Jaguar Health, Inc. on June 21, 2024. The filing details the voting results for five proposals submitted to shareholders. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol JAGX.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
All five proposals submitted at the Annual Meeting were approved by stockholders. The vote counts reported do not reflect the 1-for-60 reverse stock split effectuated on May 23, 2024.
- Proposal 1 (Election of Director): Anula Jayasuriya was elected as a Class III director for a three-year term. Votes: 84,338,214 For; 5,987,205 Withheld; 40,768,432 Broker Non-Votes.
- Proposal 2 (Auditor Ratification): Ratified the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes: 121,685,579 For; 5,235,571 Against; 4,172,701 Abstained.
- Proposal 3 (Executive Compensation): Approved, on a non-binding advisory basis, the compensation paid to named executive officers. Votes: 80,589,675 For; 7,327,567 Against; 2,408,177 Abstained; 40,768,432 Broker Non-Votes.
- Proposal 4 (Stock Incentive Plan Amendment): Approved an amendment to the 2014 Stock Incentive Plan to increase authorized shares by 45,500,000 (equivalent to 758,333 shares post-split). Votes: 70,026,219 For; 19,373,238 Against; 925,962 Abstained; 40,768,432 Broker Non-Votes.
- Proposal 5 (Adjournment Authority): Granted discretionary authority to adjourn the meeting to solicit additional proxies if necessary for Proposal 4. Votes: 81,727,219 For; 8,024,832 Against; 573,368 Abstained; 40,768,432 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) announcing the meeting results. No specific financial guidance, outlook, management commentary on operations, or new risk factors are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the impact of the 1-for-60 reverse stock split (May 23, 2024) on the reported vote counts and share ownership.
- Review the full proxy statement for detailed biographies of the elected director and specific terms of the auditor appointment.
- Examine the amended 2014 Stock Incentive Plan to understand the dilution implications of the 45,500,000 share increase.
- Consult the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.